摘要
为探讨治疗新型冠状病毒肺炎(COVID-19)的抗病毒药物在肿瘤患者中应用的药学监护策略,临床药师查阅相关文献资料,深度分析《新型冠状病毒感染的肺炎诊疗方案(试行第七版)》中推荐的抗病毒药物与抗肿瘤药物之间的药品不良反应(ADR)和药动学相互作用,提出了在COVID-19合并肿瘤患者中合理使用抗病毒药物的建议,旨在确保特殊人群的用药安全。
To discuss the pharmaceutical care strategy for Corona Virus Disease 2019(COVID-19)patients with cancer using antiviral drugs,clinical pharmacists consulted relevant literature and analyzed in depth the adverse reactions and pharmacokinetic interaction between antiviral drugs recommended in the Diagnosis and Treatment Plan for COVID-19(the 7th Tentative Version)and anti-tumor drugs.A reasonable proposal is put forward to use antiviral drugs in patients with COVID-19 combined tumors,which is aimed at ensuring the safety of drug use in special populations.
作者
黄佳
边原
王浩
钟薇
陈岷
Huang Jia;Bian Yuan;Wang Hao;Zhong Wei;Chen Min(Department of Pharmacy,Xindu District People’s Hospital of Chengdu,Sichuan Chengdu 610500,China;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital,School of Medicine,University of Electronic Science and Technology of China)
出处
《药物流行病学杂志》
CAS
2020年第6期433-438,共6页
Chinese Journal of Pharmacoepidemiology
基金
国家临床药学重点专科建设项目(编号:30305030698)
四川省教育厅四川省基层卫生事业发展研究中心课题(编号:SWFZ15-Y-29)
四川省人民医院科研基金(编号:2016LY04)
成都药学会赞邦药学科研基金(编号:201918、201919)。
